latest news releases from the newsroom
Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
ALLSCHWIL, Switzerland, March 5, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today the initial results from the double-blind, placebo-controlled, multicenter study BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension). The study met its primary objective, as treatment with bosentan (Tracleer(r)) was associated with a significant reduction in pulmonary vascular resistance PVR (p less than 0.0001).
Kahn Swick & Foti, LLC
Investor Alert -- KGS Announces Only 31 Days Left for Investors to Gain Lead Plaintiff Status in Securities Fraud Class Action Against Powerwave Technologies, Inc. -- PWAV
NEW ORLEANS, March 2, 2007 (PRIME NEWSWIRE) -- Kahn Gauthier Swick, LLC ("KGS") announces that shareholders who purchased, exchanged or otherwise acquired the common stock of Powerwave Technologies, Inc. ("Powerwave" or the "Company") (Nasdaq:PWAV) between May 2, 2005 and October 9, 2006 (the "Class Period") have only 31 days left to move for appointment as lead plaintiff in KGS' securities fraud class action lawsuit currently pending in the United States District Court for the Central District of California, Southern Division. No class has yet been certified in this action.
Labaton Sucharow LLP
Labaton Sucharow & Rudoff LLP Files Class Action Lawsuit Against Celestica, Inc., Alleging a Longer Class Period Than Existing Actions -- CLS
NEW YORK, March 2, 2007 (PRIME NEWSWIRE) -- Labaton Sucharow & Rudoff LLP filed a class action lawsuit on March 2, 2007 in the United States District Court for the Southern District of New York, on behalf of persons who purchased or otherwise acquired publicly traded securities of Celestica, Inc. ("Celestica" or the "Company") (NYSE:CLS) between January 27, 2005 and January 30, 2007, inclusive, (the "Class Period"). The lawsuit was filed against Celestica, Stephen W. Delaney (former CEO) and Anthony P. Puppi (former CFO) (collectively,"Defendants").